tranexamic acid has been researched along with Heavy Menstrual Bleeding in 136 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 9.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| "The aim of the study was to compare the efficacy of micronised flavonoids versus tranexamic acid in reducing menstrual blood loss (MBL) associated with the use of the TCu 380A intrauterine contraceptive device (IUD) in women with heavy menstrual bleeding (HMB)." | 9.27 | Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. ( Abbas, AM; Alanwar, A; Elhawwary, G; Elshabrawy, A; Eltaieb, E; Faisal, MM; Hussain, SH; Mansour, DY, 2018) |
| "Our aim was to compare the therapeutic efficacies of norethisterone acid (NETA), tranexamic acid and levonorgestrel-releasing intrauterine system (LNG-IUS) in treating idiopathic heavy menstrual bleeding (HMB)." | 9.22 | Comparison of Therapeutic Efficacies of Norethisterone, Tranexamic Acid and Levonorgestrel-Releasing Intrauterine System for the Treatment of Heavy Menstrual Bleeding: A Randomized Controlled Study. ( Evliyaoglu, O; Haberal, A; Kayikcioglu, F; Kiseli, M, 2016) |
| "To compare the efficacy of oral tranexamic acid (TA) with combined oral contraceptives (COC) in reducing menstrual blood loss (MBL) and improving quality of life in adolescent heavy menstrual bleeding (HMB)." | 9.20 | Oral Tranexamic Acid versus Combined Oral Contraceptives for Adolescent Heavy Menstrual Bleeding: A Pilot Study. ( Dietrich, JE; Mahoney, D; Sangi-Haghpeykar, H; Srivaths, LV; Yee, DL, 2015) |
| " It will be important to explore the clinical and health-care trajectories of the ECLIPSE (clinical effectiveness and cost-effectiveness of levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia) trial participants to 10 years, by which time half of the cohort will have reached menopause." | 9.20 | A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. ( Barton, P; Daniels, JP; Gray, R; Gupta, JK; Kai, J; Middleton, LJ; Pattison, HM; Prileszky, G; Roberts, TE; Sanghera, S, 2015) |
| "This study aimed at comparing the efficacy of medroxyprogesterone acetate (MPA) and tranexamic acid (TA) for treating heavy menstrual bleeding of endometrial origin (HMB)." | 9.17 | Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. ( Gandevani, SB; Goshtasebi, A; Moukhah, S, 2013) |
| "We randomly assigned 571 women with menorrhagia to treatment with levonorgestrel-IUS or usual medical treatment (tranexamic acid, mefenamic acid, combined estrogen-progestogen, or progesterone alone)." | 9.17 | Levonorgestrel intrauterine system versus medical therapy for menorrhagia. ( Daniels, J; Gray, R; Gupta, J; Kai, J; Middleton, L; Pattison, H, 2013) |
| "A multicenter, long-term, open-label study was conducted to assess the safety and health-related quality of life (HRQoL) of an oral tranexamic acid (TA) formulation in women with cyclic heavy menstrual bleeding (HMB)." | 9.15 | Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid. ( Gersten, J; Lukes, AS; Mabey, RG; Muse, K; Trott, E; Waldbaum, A, 2011) |
| "An open-label, extension clinical study was conducted to assess the safety of a novel, oral formulation of tranexamic acid (TA) in women with cyclic heavy menstrual bleeding." | 9.15 | Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. ( Adomako, TL; Baker, J; Freeman, EW; Lukes, AS; Van Drie, D, 2011) |
| "To assess the efficacy and safety of an oral formulation of tranexamic acid for the treatment of heavy menstrual bleeding." | 9.14 | Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. ( Attia, GR; Eder, SE; Edlund, M; Gersten, JK; Hecht, BR; Lukes, AS; Moore, KA; Muse, KN; Patrick, DL; Richter, HE; Rubin, A; Shangold, GA, 2010) |
| "To compare the efficacy and safety of tranexamic acid (TA) and norethisterone (NET) for the treatment of patients with ovulatory menorrhagia in China." | 9.13 | [A multicenter prospective randomized open comparative study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China]. ( Bi, SL; Cao, ZS; He, FF; Huang, HF; Huang, XL; Li, SW; Lu, JL; Lü, SL; Miao, MH; Sun, ZY; Zhang, YW; Zhang, ZY; Zhu, YM, 2008) |
| "To investigate whether medical treatment with tranexamic acid would increase the quality of life of women with heavy menstrual bleeding." | 9.09 | The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. ( Winkler, UH, 2001) |
| "To compare the efficacy and acceptability of ethamsylate, mefenamic acid, and tranexamic acid for treating menorrhagia." | 9.08 | Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. ( Bonnar, J; Sheppard, BL, 1996) |
| "To compare the efficacy and safety of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia." | 9.08 | Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. ( Adams, EJ; Cameron, IT; Preston, JT; Smith, SK, 1995) |
| " The objective was to use simple methods to study whether treatment of menorrhagia with tranexamic acid has an effect that can be detected by the women themselves." | 9.07 | [Treatment of menorrhagia with tranexamic acid. A clinical trial of an underestimated problem in general practice]. ( Drøsdal, H, 1993) |
| "To evaluate the efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding." | 8.88 | Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. ( Naoulou, B; Tsai, MC, 2012) |
| "Tranexamic acid, an oral antifibrinolytic, is due to become available soon for purchase from pharmacies without prescription for the self-management of heavy menstrual bleeding." | 8.87 | OTC tranexamic acid for heavy menstrual bleeding? ( , 2011) |
| "A 46-year-old Asian woman who was usually fit and well with no remarkable past medical history except for menorrhagia of 1-year duration for which she was receiving tranexamic acid presented to our accident and emergency department with a 2-week history of intermittent pleuritic central chest pain." | 7.96 | Bilateral pulmonary embolism while receiving tranexamic acid: a case report. ( Adjei, S; Ijaopo, EO; Ijaopo, RO, 2020) |
| "We present a case of a 30-year-old woman who suffered a central retinal artery occlusion while taking tranexamic acid." | 7.85 | Central retinal artery occlusion in a 30-year-old woman taking tranexamic acid. ( Sharma, B; Wijetilleka, S; Yeo, DCM, 2017) |
| "Although intravascular thrombi and infarct-type necrosis have been reported in leiomyomas following tranexamic acid therapy, intratumoral vasculopathy resembling acute atherosis has not been reported to date in patients without exposure to gonadotropin receptor agonist." | 7.85 | Intratumoral Vasculopathy in Leiomyoma Treated With Tranexamic Acid. ( Krigman, HR; Kudose, S, 2017) |
| "To evaluate the efficacy and safety of oral, modified-release tranexamic acid in women with heavy menstrual bleeding and fibroids." | 7.79 | Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids. ( Adomako, TL; Baker, J; Eder, S; Gersten, J; Mabey, RG, 2013) |
| "To assess whether use of tranexamic acid is associated with an increased risk of venous thromboembolism (VTE)." | 7.75 | The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. ( Alfredsson, L; Kieler, H; Seaman, H; Sundström, A, 2009) |
| "Infarct-type necrosis was observed in the leiomyomas of 38 patients, 22 of whom had tranexamic acid (15%) whereas the remaining 16 had no drug exposure (4." | 7.74 | Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. ( Chan, QK; Cheung, AN; Cheung, CL; Ip, PP; Lam, KW; Pun, TC; Yeung, MC, 2007) |
| "To determine the efficacy of tranexamic acid in the treatment of idiopathic menorrhgia and to investigate the effect of medical treatment with tranexamic acid on the quality of life of the women with idiopathic menorrhagia." | 7.73 | Treatment of idiopathic menorrhagia with tranexamic acid. ( Jaisamrarn, U; Srinil, S, 2005) |
| "Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 7.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
| "The objective of this study was to investigate the effects of tranexamic acid on uterine vascular resistance in women with dysfunctional uterine bleeding and in women with menorrhagia associated with fibroids." | 7.70 | Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid. ( Hardiman, P; Lakhani, KP; Marsh, MS; Purcell, W, 1998) |
| "5 gm three times a day for 3 days and 1 gm twice a day for another 2 days), and an intrauterine contraceptive device releasing 20 micrograms levonorgestrel per day was compared in women with idiopathic menorrhagia." | 7.68 | A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. ( Andersch, B; Andersson, K; Milsom, I; Rybo, G, 1991) |
| "Two randomized, open-label clinical studies involving healthy female volunteers aged 18-45 years (study 1, N = 32; study 2, N = 40) are described, which characterize the pharmacokinetics and steady-state dosage regimen performance of 2 novel, modified-release tranexamic acid tablet formulations." | 6.77 | Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. ( Lavigne, JR; Marenco, T; Moore, KA; Morelli, G; Morin, I, 2012) |
| "Tranexamic acid is a well-tolerated, cost-effective drug that reduces menstrual blood loss in the range of 34-59%." | 6.47 | Tranexamic acid therapy for heavy menstrual bleeding. ( Lumsden, MA; Wedisinghe, L, 2011) |
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 5.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| " Prophylaxis (Desmopressin, clotting factor concentrates or tranexamic acid) to prevent bleeding was described in 100% (30/30) of EA procedures and in 4% (24/661) of hysterectomies." | 5.41 | Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. ( Bongers, MY; Eising, HP; Leemans, JC; Punt, MC, 2023) |
| "Tranexamic acid is an antifibrinolytic drug." | 5.39 | Tranexamic acid and thrombosis. ( , 2013) |
| " Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 5.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
| "The aim of the study was to compare the efficacy of micronised flavonoids versus tranexamic acid in reducing menstrual blood loss (MBL) associated with the use of the TCu 380A intrauterine contraceptive device (IUD) in women with heavy menstrual bleeding (HMB)." | 5.27 | Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. ( Abbas, AM; Alanwar, A; Elhawwary, G; Elshabrawy, A; Eltaieb, E; Faisal, MM; Hussain, SH; Mansour, DY, 2018) |
| "Our aim was to compare the therapeutic efficacies of norethisterone acid (NETA), tranexamic acid and levonorgestrel-releasing intrauterine system (LNG-IUS) in treating idiopathic heavy menstrual bleeding (HMB)." | 5.22 | Comparison of Therapeutic Efficacies of Norethisterone, Tranexamic Acid and Levonorgestrel-Releasing Intrauterine System for the Treatment of Heavy Menstrual Bleeding: A Randomized Controlled Study. ( Evliyaoglu, O; Haberal, A; Kayikcioglu, F; Kiseli, M, 2016) |
| "To compare the efficacy of oral tranexamic acid (TA) with combined oral contraceptives (COC) in reducing menstrual blood loss (MBL) and improving quality of life in adolescent heavy menstrual bleeding (HMB)." | 5.20 | Oral Tranexamic Acid versus Combined Oral Contraceptives for Adolescent Heavy Menstrual Bleeding: A Pilot Study. ( Dietrich, JE; Mahoney, D; Sangi-Haghpeykar, H; Srivaths, LV; Yee, DL, 2015) |
| " It will be important to explore the clinical and health-care trajectories of the ECLIPSE (clinical effectiveness and cost-effectiveness of levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia) trial participants to 10 years, by which time half of the cohort will have reached menopause." | 5.20 | A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. ( Barton, P; Daniels, JP; Gray, R; Gupta, JK; Kai, J; Middleton, LJ; Pattison, HM; Prileszky, G; Roberts, TE; Sanghera, S, 2015) |
| "This study aimed at comparing the efficacy of medroxyprogesterone acetate (MPA) and tranexamic acid (TA) for treating heavy menstrual bleeding of endometrial origin (HMB)." | 5.17 | Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. ( Gandevani, SB; Goshtasebi, A; Moukhah, S, 2013) |
| "We randomly assigned 571 women with menorrhagia to treatment with levonorgestrel-IUS or usual medical treatment (tranexamic acid, mefenamic acid, combined estrogen-progestogen, or progesterone alone)." | 5.17 | Levonorgestrel intrauterine system versus medical therapy for menorrhagia. ( Daniels, J; Gray, R; Gupta, J; Kai, J; Middleton, L; Pattison, H, 2013) |
| "An open-label, extension clinical study was conducted to assess the safety of a novel, oral formulation of tranexamic acid (TA) in women with cyclic heavy menstrual bleeding." | 5.15 | Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. ( Adomako, TL; Baker, J; Freeman, EW; Lukes, AS; Van Drie, D, 2011) |
| "A multicenter, long-term, open-label study was conducted to assess the safety and health-related quality of life (HRQoL) of an oral tranexamic acid (TA) formulation in women with cyclic heavy menstrual bleeding (HMB)." | 5.15 | Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid. ( Gersten, J; Lukes, AS; Mabey, RG; Muse, K; Trott, E; Waldbaum, A, 2011) |
| "We sought to assess the efficacy and safety of 2 dosing regimens of a novel, oral tranexamic acid formulation (Lysteda; Ferring Pharmaceuticals Inc, Parsippany, NJ) in women with cyclic heavy menstrual bleeding." | 5.15 | A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. ( Adomako, TL; Freeman, EW; Gersten, J; Lukes, A; Mabey, RG; VanDrie, D, 2011) |
| "To assess the efficacy and safety of an oral formulation of tranexamic acid for the treatment of heavy menstrual bleeding." | 5.14 | Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. ( Attia, GR; Eder, SE; Edlund, M; Gersten, JK; Hecht, BR; Lukes, AS; Moore, KA; Muse, KN; Patrick, DL; Richter, HE; Rubin, A; Shangold, GA, 2010) |
| "To compare the efficacy and safety of tranexamic acid (TA) and norethisterone (NET) for the treatment of patients with ovulatory menorrhagia in China." | 5.13 | [A multicenter prospective randomized open comparative study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China]. ( Bi, SL; Cao, ZS; He, FF; Huang, HF; Huang, XL; Li, SW; Lu, JL; Lü, SL; Miao, MH; Sun, ZY; Zhang, YW; Zhang, ZY; Zhu, YM, 2008) |
| "Currently, tranexamic acid (TXA) is used as 4 g/day in menorrhagia This prospective randomised study included 100 cases to assess efficacy and safety of 2 g/day TXA in dysfunctional uterine bleeding (DUB) vs cyclical 10 mg twice-daily medroxyprogesterone acetate (MPA) for 3 cycles." | 5.12 | Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. ( Agarwal, N; Diwakar, S; Kriplani, A; Kulshrestha, V, 2006) |
| "To investigate whether tranexamic acid (Transamin) therapy reduces the amount of menstrual blood loss (MBL) and occurrence of menorrhagia after intrauterine device (IUD) insertion." | 5.12 | Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. ( Dou, LX; Gao, ES; Li, D; Lin, X; Yuan, W; Zhang, M, 2007) |
| " Systematic review and meta-analysis to determine the bleeding rates associated with tranexamic acid, desmopressin, platelet transfusion, plasma transfusion and recombinant activated factor VII, for patients with unclassified bleeding disorders undergoing surgery, childbirth or with menorrhagia." | 5.12 | Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies. ( Desborough, MJR; Doree, C; Lowe, GC; Obaji, S; Thomas, W, 2021) |
| "To investigate whether medical treatment with tranexamic acid would increase the quality of life of women with heavy menstrual bleeding." | 5.09 | The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. ( Winkler, UH, 2001) |
| "To compare the efficacy and safety of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia." | 5.08 | Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. ( Adams, EJ; Cameron, IT; Preston, JT; Smith, SK, 1995) |
| "To compare the efficacy and acceptability of ethamsylate, mefenamic acid, and tranexamic acid for treating menorrhagia." | 5.08 | Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. ( Bonnar, J; Sheppard, BL, 1996) |
| " The objective was to use simple methods to study whether treatment of menorrhagia with tranexamic acid has an effect that can be detected by the women themselves." | 5.07 | [Treatment of menorrhagia with tranexamic acid. A clinical trial of an underestimated problem in general practice]. ( Drøsdal, H, 1993) |
| "Tranexamic acid (TA), an antifibrinolytic drug, is usually administered orally to women with menorrhagia." | 5.07 | Vaginal absorption of low-dose tranexamic acid from impregnated tampons. ( Cohen, M; Devraj, K; Dutton, M; Moodley, J, 1992) |
| " Tranexamic acid (TXA) is one of the most commonly used and widely researched antifibrinolytic agents; its role in postpartum hemorrhage, menorrhagia, trauma-associated hemorrhage, and surgical bleeding has been well defined." | 5.05 | The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. ( Al-Samkari, H; Cai, J; DeLoughery, TG; Olson, S; Raghunathan, V; Ribkoff, J; Shatzel, JJ, 2020) |
| "8%) had menorrhagia, for which combined oral contraceptives, tranexamic acid and desmopressin were the most common first-line therapies for menorrhagia, whereas VWF was third-line therapy reported in 13 women (1." | 4.93 | Von Willebrand factor for menorrhagia: a survey and literature review. ( Brambilla, DJ; James, AH; Kessler, CM; Konkle, BA; Kouides, PA; Machin, N; Malec, LM; Neff, AT; Philipp, CS; Ragni, MV, 2016) |
| "To evaluate the efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding." | 4.88 | Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. ( Naoulou, B; Tsai, MC, 2012) |
| "Tranexamic acid, an oral antifibrinolytic, is due to become available soon for purchase from pharmacies without prescription for the self-management of heavy menstrual bleeding." | 4.87 | OTC tranexamic acid for heavy menstrual bleeding? ( , 2011) |
| "A 46-year-old Asian woman who was usually fit and well with no remarkable past medical history except for menorrhagia of 1-year duration for which she was receiving tranexamic acid presented to our accident and emergency department with a 2-week history of intermittent pleuritic central chest pain." | 3.96 | Bilateral pulmonary embolism while receiving tranexamic acid: a case report. ( Adjei, S; Ijaopo, EO; Ijaopo, RO, 2020) |
| "We present a case of a 30-year-old woman who suffered a central retinal artery occlusion while taking tranexamic acid." | 3.85 | Central retinal artery occlusion in a 30-year-old woman taking tranexamic acid. ( Sharma, B; Wijetilleka, S; Yeo, DCM, 2017) |
| "Although intravascular thrombi and infarct-type necrosis have been reported in leiomyomas following tranexamic acid therapy, intratumoral vasculopathy resembling acute atherosis has not been reported to date in patients without exposure to gonadotropin receptor agonist." | 3.85 | Intratumoral Vasculopathy in Leiomyoma Treated With Tranexamic Acid. ( Krigman, HR; Kudose, S, 2017) |
| "To evaluate the efficacy and safety of oral, modified-release tranexamic acid in women with heavy menstrual bleeding and fibroids." | 3.79 | Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids. ( Adomako, TL; Baker, J; Eder, S; Gersten, J; Mabey, RG, 2013) |
| " We are reporting the case of a 47-year-old lady, taking tranexamic acid for menorrhagia, who presented with shortness of breath and was diagnosed with extensive bilateral PE." | 3.79 | The great deception: tranexamic acid and extensive pulmonary emboli. ( King, C; Mak, V; Orhan, O; Salam, A, 2013) |
| "To assess whether use of tranexamic acid is associated with an increased risk of venous thromboembolism (VTE)." | 3.75 | The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. ( Alfredsson, L; Kieler, H; Seaman, H; Sundström, A, 2009) |
| "Infarct-type necrosis was observed in the leiomyomas of 38 patients, 22 of whom had tranexamic acid (15%) whereas the remaining 16 had no drug exposure (4." | 3.74 | Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. ( Chan, QK; Cheung, AN; Cheung, CL; Ip, PP; Lam, KW; Pun, TC; Yeung, MC, 2007) |
| "To determine the efficacy of tranexamic acid in the treatment of idiopathic menorrhgia and to investigate the effect of medical treatment with tranexamic acid on the quality of life of the women with idiopathic menorrhagia." | 3.73 | Treatment of idiopathic menorrhagia with tranexamic acid. ( Jaisamrarn, U; Srinil, S, 2005) |
| "Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 3.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
| "The objective of this study was to investigate the effects of tranexamic acid on uterine vascular resistance in women with dysfunctional uterine bleeding and in women with menorrhagia associated with fibroids." | 3.70 | Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid. ( Hardiman, P; Lakhani, KP; Marsh, MS; Purcell, W, 1998) |
| "Central venous stasis retinopathy (CVSR) was observed in two young women following the administration of oral tranexamic acid (TA) for the treatment of menorrhagia." | 3.68 | Central venous stasis retinopathy following the use of tranexamic acid. ( Axer-Siegel, R; Buckman, G; Snir, M; Yassur, Y, 1990) |
| "5 gm three times a day for 3 days and 1 gm twice a day for another 2 days), and an intrauterine contraceptive device releasing 20 micrograms levonorgestrel per day was compared in women with idiopathic menorrhagia." | 3.68 | A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. ( Andersch, B; Andersson, K; Milsom, I; Rybo, G, 1991) |
| "Menorrhagia is a regular menstrual cycle lasting more than seven days and/or blood loss over 80 mL per cycle." | 2.90 | "Evaluation of the effect of roasted lentil flour (lentil savigh) as a functional food in menstrual bleeding reduction". ( Amouzegar, H; Heidari, A; Khani, S; Nojavan, F; Shafiee, M, 2019) |
| "Treatment with mefenamic acid resulted in less volume of blood loss compared to tranexamic acid (MD -64." | 2.82 | Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use. ( Christelle, K; Jaafar, SH; Norhayati, MN, 2022) |
| "Two randomized, open-label clinical studies involving healthy female volunteers aged 18-45 years (study 1, N = 32; study 2, N = 40) are described, which characterize the pharmacokinetics and steady-state dosage regimen performance of 2 novel, modified-release tranexamic acid tablet formulations." | 2.77 | Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. ( Lavigne, JR; Marenco, T; Moore, KA; Morelli, G; Morin, I, 2012) |
| "A dichotomy exists within the treatment of heavy menstrual bleeding (HMB); guidelines and expert opinion recommend that clinical management be guided by subjective, patient-centered measures, yet clinical trials often describe treatment efficacy in terms of objective reductions in menstrual blood loss (MBL)." | 2.75 | Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. ( Lukes, AS; Moore, KA; Muse, K; Patrick, DL; Richter, HE, 2010) |
| "Heavy menstrual bleeding was classically defined as greater than or equal to 80 mL of blood loss per menstrual cycle." | 2.66 | Progestogen-releasing intrauterine systems for heavy menstrual bleeding. ( Bofill Rodriguez, M; Jordan, V; Lethaby, A, 2020) |
| "Tranexamic acid is an effective treatment to reduce the volume of bleeding during menstruation." | 2.61 | Applications of Tranexamic acid in benign gynecology. ( Ingraham, CF; Klebanoff, JS; Marfori, CQ; Moawad, GN; Wu, CZ, 2019) |
| "The most common form of BDs is von Willebrand Disease, reflecting 13% of adolescents with AUB." | 2.58 | Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders. ( Deligeoroglou, E; Karountzos, V, 2018) |
| "Tranexamic acid (TXA) is a synthetic anti-fibrinolytic agent commonly used for the prevention and treatment of bleeding disorders." | 2.55 | Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature. ( Chow, KM; Kwan, BC; Leung, CB; Li, PK; Ma, TK; Szeto, CC, 2017) |
| "The most robust data for the treatment of menorrhagia are for tranexamic acid." | 2.47 | Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. ( Bates, JS; Buie, LW; Woodis, CB, 2011) |
| "Tranexamic acid is a well-tolerated, cost-effective drug that reduces menstrual blood loss in the range of 34-59%." | 2.47 | Tranexamic acid therapy for heavy menstrual bleeding. ( Lumsden, MA; Wedisinghe, L, 2011) |
| "Menorrhagia is defined as menstrual periods lasting more than 7 days and/or involving blood loss greater than 80ml." | 2.46 | Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. ( Agostini, A; Bazot, M; Brailly-Tabard, S; Brun, JL; Chabbert-Buffet, N; Cravello, L; De Raucourt, E; Fauconnier, A; Fernandez, H; Gervaise, A; Golfier, F; Gompel, A; Gondry, J; Graesslin, O; Huchon, C; Lucot, JP; Marret, H; Plu-Bureau, G; Roman, H, 2010) |
| "In vWD, the treatment of menorrhagia is usually medical, but there is lack of prospective data on the efficacy of commonly used medical therapies in these women." | 2.43 | Women and von Willebrand disease: controversies in diagnosis and management. ( Chi, C; Kadir, RA, 2006) |
| "Melasma is an acquired melanogenesis dysfunction resulting in chronic hyperpigmentation commonly affecting the face and other frequently sun-exposed areas of the body." | 1.72 | Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio. ( Peng, L; Simpson, J; Ting, W, 2022) |
| "Approximately 50% of female carriers of hemophilia A have factor VIII (FVIII) levels below 0." | 1.56 | Hemophilia A in Females: Considerations for Clinical Management. ( Boukouvala, A; Bryant, P; McDaniel, J; Nance, D, 2020) |
| "Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life." | 1.51 | Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION SUMMARY, Number 785. ( , 2019) |
| "Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life." | 1.51 | Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785. ( , 2019) |
| "She had no further episodes of convulsion till dis-charge and during the two months of follow-up." | 1.40 | Tranexamic acid overdosage-induced generalized seizure in renal failure. ( Agarwal, SK; Bhat, A; Bhowmik, DM; Dogra, M; Vibha, D, 2014) |
| "Tranexamic acid is an antifibrinolytic drug." | 1.39 | Tranexamic acid and thrombosis. ( , 2013) |
| "Daily MBLs and Menorrhagia Impact Questionnaire scores were evaluated for two pretreatment cycles and the first three tranexamic acid treatment cycles of each study." | 1.38 | Daily menstrual blood loss and quality of life in women with heavy menstrual bleeding. ( Adomako, TL; Baker, J; Eder, S; Lukes, AS, 2012) |
| "Menorrhagia is a common and important problem that has a significant impact on women's health." | 1.38 | Trends in the surgical options for the treatment of menorrhagia in Scotland: examination of health episode statistics, 2000-2008. ( Chittenden, BG; Dallas, S; Jack, SA, 2012) |
| "Heavy menstrual bleeding is associated with increased local fibrinolysis." | 1.37 | Antifibrinolytics in women with menorrhagia. ( Philipp, CS, 2011) |
| "The appropriate treatment of menorrhagia improves patients' quality of life." | 1.36 | [Update on current care guidelines: evaluation and treatment of menorrhagia]. ( , 2010) |
| "Medroxyprogesterone acetate treatment for her dysfunctional uterine bleeding was unsuccessful." | 1.32 | Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review. ( Osswald, M; Repine, T, 2004) |
| " Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 1.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
| " Local administration is more advantageous than the oral approach because smaller dosage is required and side effects thus reduced." | 1.26 | Hemorrhage induced by intrauterine devices: control by local proteinase inhibition. ( Herting, W; Tauber, PF; Wolf, AS; Zaneveld, LJ, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (9.56) | 18.7374 |
| 1990's | 20 (14.71) | 18.2507 |
| 2000's | 28 (20.59) | 29.6817 |
| 2010's | 61 (44.85) | 24.3611 |
| 2020's | 14 (10.29) | 2.80 |
| Authors | Studies |
|---|---|
| Brignardello-Petersen, R | 1 |
| El Alayli, A | 1 |
| Husainat, N | 1 |
| Kalot, MA | 1 |
| Shahid, S | 1 |
| Aljabirii, Y | 1 |
| Britt, A | 1 |
| Alturkmani, H | 1 |
| El-Khechen, H | 1 |
| Motaghi, S | 1 |
| Roller, J | 1 |
| Abdul-Kadir, R | 1 |
| Couper, S | 1 |
| Kouides, P | 2 |
| Lavin, M | 1 |
| Ozelo, MC | 1 |
| Weyand, A | 1 |
| James, PD | 2 |
| Connell, NT | 1 |
| Flood, VH | 1 |
| Mustafa, RA | 1 |
| Simpson, J | 1 |
| Peng, L | 1 |
| Ting, W | 1 |
| Christelle, K | 1 |
| Norhayati, MN | 1 |
| Jaafar, SH | 1 |
| Ragni, MV | 2 |
| Rothenberger, SD | 1 |
| Feldman, R | 1 |
| Nance, D | 2 |
| Leavitt, AD | 1 |
| Malec, L | 1 |
| Kulkarni, R | 2 |
| Sidonio, R | 1 |
| Kraut, E | 1 |
| Lasky, J | 1 |
| Pruthi, R | 1 |
| Angelini, D | 1 |
| Philipp, C | 1 |
| Hwang, N | 1 |
| Wheeler, AP | 1 |
| Seaman, C | 1 |
| Machin, N | 2 |
| Xavier, F | 1 |
| Meyer, M | 1 |
| Bellissimo, D | 1 |
| Humphreys, G | 1 |
| Smith, KJ | 1 |
| Merricks, EP | 1 |
| Nichols, TC | 1 |
| Ivanco, D | 1 |
| Vehec, D | 1 |
| Koerbel, G | 1 |
| Althouse, AD | 1 |
| Eising, HP | 1 |
| Punt, MC | 1 |
| Leemans, JC | 1 |
| Bongers, MY | 1 |
| Bofill Rodriguez, M | 2 |
| Lethaby, A | 5 |
| Low, C | 1 |
| Cameron, IT | 3 |
| Cai, J | 1 |
| Ribkoff, J | 1 |
| Olson, S | 1 |
| Raghunathan, V | 1 |
| Al-Samkari, H | 1 |
| DeLoughery, TG | 1 |
| Shatzel, JJ | 1 |
| Bryant, P | 1 |
| Boukouvala, A | 1 |
| McDaniel, J | 1 |
| Meaidi, A | 1 |
| Kuhr Skals, R | 1 |
| Alexander Gerds, T | 1 |
| Lidegaard, O | 1 |
| Torp-Pedersen, C | 1 |
| Jordan, V | 1 |
| Umarami, RBR | 1 |
| Roqaiya, M | 1 |
| Quadri, MA | 1 |
| Lale, A | 1 |
| Halajian, E | 1 |
| Guthmann, R | 1 |
| Nashelsky, J | 1 |
| Ijaopo, EO | 1 |
| Ijaopo, RO | 1 |
| Adjei, S | 1 |
| Desborough, MJR | 1 |
| Obaji, S | 1 |
| Lowe, GC | 1 |
| Doree, C | 1 |
| Thomas, W | 1 |
| Lim, MY | 1 |
| Olson, L | 1 |
| Rajpurkar, MA | 1 |
| Weyand, AC | 1 |
| Klok, FA | 1 |
| Schreiber, K | 1 |
| Stach, K | 1 |
| Ageno, W | 1 |
| Middeldorp, S | 1 |
| Eichinger, S | 1 |
| Delluc, A | 1 |
| Blondon, M | 1 |
| Ay, C | 1 |
| Wijetilleka, S | 1 |
| Yeo, DCM | 1 |
| Sharma, B | 1 |
| Deligeoroglou, E | 2 |
| Karountzos, V | 2 |
| Boonyawat, K | 1 |
| O'Brien, SH | 2 |
| Bates, SM | 1 |
| Thorne, JG | 1 |
| Reid, RL | 1 |
| Bryant-Smith, AC | 1 |
| Farquhar, C | 3 |
| Hickey, M | 1 |
| Alanwar, A | 1 |
| Abbas, AM | 1 |
| Hussain, SH | 1 |
| Elhawwary, G | 1 |
| Mansour, DY | 1 |
| Faisal, MM | 1 |
| Elshabrawy, A | 1 |
| Eltaieb, E | 1 |
| Saini, S | 1 |
| Ziegler, H | 1 |
| Christian-Rancy, M | 1 |
| Ahuja, S | 1 |
| Hege, K | 1 |
| Savelli, SL | 1 |
| Vesely, SK | 1 |
| Klebanoff, JS | 1 |
| Marfori, CQ | 1 |
| Ingraham, CF | 1 |
| Wu, CZ | 1 |
| Moawad, GN | 1 |
| Shafiee, M | 1 |
| Heidari, A | 1 |
| Amouzegar, H | 1 |
| Khani, S | 1 |
| Nojavan, F | 1 |
| Moore, AA | 1 |
| Goshtasebi, A | 1 |
| Moukhah, S | 1 |
| Gandevani, SB | 1 |
| Matteson, KA | 1 |
| Rahn, DD | 1 |
| Wheeler, TL | 1 |
| Casiano, E | 1 |
| Siddiqui, NY | 1 |
| Harvie, HS | 1 |
| Mamik, MM | 1 |
| Balk, EM | 1 |
| Sung, VW | 1 |
| Eder, S | 2 |
| Baker, J | 3 |
| Gersten, J | 3 |
| Mabey, RG | 4 |
| Adomako, TL | 5 |
| Gybel, M | 1 |
| Kristensen, K | 1 |
| Roseva-Nielsen, N | 1 |
| Bhat, A | 1 |
| Bhowmik, DM | 1 |
| Vibha, D | 1 |
| Dogra, M | 1 |
| Agarwal, SK | 1 |
| Ray, S | 2 |
| Ray, A | 2 |
| Bitzer, J | 1 |
| Heikinheimo, O | 1 |
| Nelson, AL | 1 |
| Calaf-Alsina, J | 1 |
| Fraser, IS | 2 |
| Srivaths, LV | 1 |
| Dietrich, JE | 1 |
| Yee, DL | 1 |
| Sangi-Haghpeykar, H | 1 |
| Mahoney, D | 1 |
| Bradley, LD | 1 |
| Gueye, NA | 1 |
| Gupta, JK | 1 |
| Daniels, JP | 1 |
| Middleton, LJ | 1 |
| Pattison, HM | 1 |
| Prileszky, G | 1 |
| Roberts, TE | 1 |
| Sanghera, S | 1 |
| Barton, P | 1 |
| Gray, R | 2 |
| Kai, J | 2 |
| Malec, LM | 1 |
| James, AH | 1 |
| Kessler, CM | 1 |
| Konkle, BA | 1 |
| Kouides, PA | 4 |
| Neff, AT | 1 |
| Philipp, CS | 3 |
| Brambilla, DJ | 1 |
| Kiseli, M | 1 |
| Kayikcioglu, F | 1 |
| Evliyaoglu, O | 1 |
| Haberal, A | 1 |
| Ma, TK | 1 |
| Chow, KM | 1 |
| Kwan, BC | 1 |
| Leung, CB | 1 |
| Szeto, CC | 1 |
| Li, PK | 1 |
| Kudose, S | 1 |
| Krigman, HR | 1 |
| Zhang, YW | 1 |
| He, FF | 1 |
| Sun, ZY | 1 |
| Li, SW | 1 |
| Bi, SL | 1 |
| Huang, XL | 1 |
| Cao, ZS | 1 |
| Lü, SL | 1 |
| Lu, JL | 1 |
| Zhang, ZY | 1 |
| Zhu, YM | 1 |
| Huang, HF | 1 |
| Miao, MH | 1 |
| Sundström, A | 1 |
| Seaman, H | 1 |
| Kieler, H | 1 |
| Alfredsson, L | 1 |
| Byams, VR | 1 |
| Stein, SF | 1 |
| Heit, JA | 1 |
| Lukes, AS | 8 |
| Skerrette, NI | 1 |
| Dowling, NF | 1 |
| Evatt, BL | 1 |
| Miller, CH | 1 |
| Owens, S | 1 |
| Marret, H | 1 |
| Fauconnier, A | 1 |
| Chabbert-Buffet, N | 1 |
| Cravello, L | 1 |
| Golfier, F | 1 |
| Gondry, J | 1 |
| Agostini, A | 1 |
| Bazot, M | 1 |
| Brailly-Tabard, S | 1 |
| Brun, JL | 1 |
| De Raucourt, E | 1 |
| Gervaise, A | 1 |
| Gompel, A | 1 |
| Graesslin, O | 1 |
| Huchon, C | 1 |
| Lucot, JP | 1 |
| Plu-Bureau, G | 1 |
| Roman, H | 1 |
| Fernandez, H | 1 |
| Moore, KA | 6 |
| Callahan, TS | 1 |
| Maison-Blanche, P | 1 |
| Morin, I | 2 |
| Marenco, T | 2 |
| Swearingen, D | 1 |
| Olbertz, J | 1 |
| Muse, KN | 1 |
| Gersten, JK | 2 |
| Hecht, BR | 1 |
| Edlund, M | 3 |
| Richter, HE | 3 |
| Eder, SE | 1 |
| Attia, GR | 1 |
| Patrick, DL | 3 |
| Rubin, A | 2 |
| Shangold, GA | 1 |
| Mikhail, S | 1 |
| Muse, K | 3 |
| Bushnell, DM | 1 |
| Martin, ML | 1 |
| Lippi, G | 1 |
| Cervellin, G | 1 |
| Franchini, M | 1 |
| Lavigne, JR | 1 |
| Morelli, G | 1 |
| Juvkam, KH | 1 |
| Gudim, HB | 1 |
| Levy, R | 1 |
| Prasad, S | 1 |
| Rowland, K | 1 |
| Lumsden, MA | 1 |
| Wedisinghe, L | 1 |
| Freeman, EW | 2 |
| Lukes, A | 1 |
| VanDrie, D | 1 |
| Waldbaum, A | 2 |
| Trott, E | 1 |
| Van Drie, D | 1 |
| Bates, JS | 1 |
| Buie, LW | 1 |
| Woodis, CB | 1 |
| Roberts, I | 1 |
| Naoulou, B | 1 |
| Tsai, MC | 1 |
| Chittenden, BG | 1 |
| Dallas, S | 1 |
| Jack, SA | 1 |
| Creatsas, G | 1 |
| Abu Hashim, H | 1 |
| Gupta, J | 1 |
| Middleton, L | 1 |
| Pattison, H | 1 |
| Daniels, J | 1 |
| Salam, A | 1 |
| King, C | 1 |
| Orhan, O | 1 |
| Mak, V | 1 |
| Römer, T | 1 |
| Robins, JC | 1 |
| Duckitt, K | 6 |
| Wellington, K | 1 |
| Wagstaff, AJ | 1 |
| Mohri, H | 1 |
| Iacobellis, G | 2 |
| Repine, T | 1 |
| Osswald, M | 1 |
| Mannucci, PM | 1 |
| McCully, K | 3 |
| Kadir, RA | 1 |
| Chi, C | 1 |
| Kriplani, A | 1 |
| Kulshrestha, V | 1 |
| Agarwal, N | 1 |
| Diwakar, S | 1 |
| Aydinok, Y | 1 |
| Egemen, A | 1 |
| Balkan, C | 1 |
| Ip, PP | 1 |
| Lam, KW | 1 |
| Cheung, CL | 1 |
| Yeung, MC | 1 |
| Pun, TC | 1 |
| Chan, QK | 1 |
| Cheung, AN | 1 |
| Lin, X | 1 |
| Gao, ES | 1 |
| Li, D | 1 |
| Zhang, M | 1 |
| Dou, LX | 1 |
| Yuan, W | 1 |
| Srinil, S | 1 |
| Jaisamrarn, U | 1 |
| Porte, RJ | 1 |
| Burns, JW | 1 |
| Goodpasture, JC | 1 |
| Friel, P | 1 |
| Wheeler, R | 1 |
| Zaneveld, LJ | 2 |
| Ylikorkala, O | 2 |
| Viinikka, L | 1 |
| Petersen, K | 1 |
| Jelert, H | 1 |
| Diernaes, E | 1 |
| Detlefsen, GU | 1 |
| Preston, JT | 1 |
| Adams, EJ | 1 |
| Smith, SK | 3 |
| Gleeson, NC | 1 |
| Buggy, F | 1 |
| Sheppard, BL | 3 |
| Bonnar, J | 3 |
| Drøsdal, H | 1 |
| Tjønnfjord, GE | 1 |
| Brosstad, F | 1 |
| Liddell, H | 1 |
| Cooper, KG | 1 |
| Parkin, DE | 1 |
| Garratt, AM | 1 |
| Grant, AM | 1 |
| Lakhani, KP | 1 |
| Marsh, MS | 1 |
| Purcell, W | 1 |
| Hardiman, P | 1 |
| Shaw, RW | 1 |
| Ong, YL | 1 |
| Hull, DR | 1 |
| Mayne, EE | 1 |
| Onundarson, PT | 1 |
| Fender, GR | 2 |
| Prentice, A | 3 |
| Gorst, T | 2 |
| Nixon, RM | 2 |
| Duffy, SW | 2 |
| Day, NE | 2 |
| Irvine, GA | 1 |
| Cooke, I | 2 |
| Hope, S | 1 |
| Turner, E | 1 |
| Bowie, P | 1 |
| McMullen, KW | 1 |
| Kellock, C | 1 |
| Winkler, UH | 1 |
| Blombäck, M | 1 |
| Fried, G | 1 |
| Ragab, MI | 1 |
| Thomas, MN | 1 |
| Tauber, PF | 1 |
| Wolf, AS | 1 |
| Herting, W | 1 |
| Nilsson, IM | 1 |
| Prentice, CR | 1 |
| Hahn, L | 1 |
| Rybo, G | 3 |
| Valsecchi, A | 1 |
| Cappelletti, M | 1 |
| Bar-Am, A | 1 |
| Toaf, FR | 1 |
| Hertzberg, M | 1 |
| Moodley, J | 1 |
| Cohen, M | 1 |
| Devraj, K | 1 |
| Dutton, M | 1 |
| Milsom, I | 2 |
| Andersson, K | 1 |
| Andersch, B | 2 |
| Barthwal, M | 1 |
| Srivastava, K | 1 |
| Birgerson, L | 1 |
| Bright-Paul, R | 1 |
| Snir, M | 1 |
| Axer-Siegel, R | 1 |
| Buckman, G | 1 |
| Yassur, Y | 1 |
| Dockeray, CJ | 1 |
| Daly, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding[NCT05345613] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| The Use of Peri-Operative Intravenous Estrogen for the Mitigation of Ischemia Reperfusion Injury in the Setting of Renal Transplantation[NCT03663543] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-08-26 | Active, not recruiting | ||
| Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study[NCT02606045] | Phase 3 | 60 participants (Anticipated) | Interventional | 2019-02-07 | Active, not recruiting | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Peroperative Tranexamic Acid as Prophylaxis of Haemorrhage in Benign Hysterectomy - a Randomized, Placebo-controlled Trial[NCT01940419] | Phase 4 | 332 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia[NCT00386308] | Phase 3 | 196 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia[NCT00401193] | Phase 3 | 304 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study[NCT02163525] | 114 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | |||
| Multicenter Study to Evaluate the Safety of XP12B in Women With Heavy Menstrual Bleeding Associated With Menorrhagia[NCT00113568] | Phase 3 | 784 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| The Trust (Treatment Results of Uterine Sparing Technologies) Study[NCT01563783] | 84 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Reduce Bleeding in Premenopausal Women With Abnormal Uterine Bleeding: A Pilot Study[NCT01493791] | Early Phase 1 | 0 participants (Actual) | Interventional | 2011-11-08 | Withdrawn | ||
| The LUSTOR (Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions)Trial[NCT01750008] | 51 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Single Dose Tranexamic Acid for Dacryocystorhinostomy[NCT01221909] | 80 participants (Anticipated) | Interventional | 2010-12-31 | Not yet recruiting | |||
| National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042] | 1,100 participants (Anticipated) | Observational | 2007-07-31 | Completed | |||
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| Effect of Intravenous Tranexamic Acid Plus Intramyometrial Desmopressin on Blood Loss During Laparoscopic Myomectomy: Randomized, Double-blind, Placebo-controlled Trial[NCT05517590] | 100 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | |||
| Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery: A Double Blind Randomized Controlled Trial[NCT01111669] | 28 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
reduction of menstrual blood loss in mL (NCT00386308)
Timeframe: Baseline MBL over 6 menstrual cycles
| Intervention | mL (Least Squares Mean) |
|---|---|
| 3900 mg/Day | 66 |
| Placebo | 18 |
A positive unit change mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited (NCT00386308)
Timeframe: Change from Baseline scores over 6 menstrual cycles
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 3900 mg/Day | 0.9 |
| Placebo | 0.4 |
A positive unit change mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited (NCT00386308)
Timeframe: Change from Baseline scores over 6 menstrual cycles
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 3900 mg/Day | 0.9 |
| Placebo | 0.4 |
Percentage of subjects who experienced a reduction from baseline in the frequency of large stains (NCT00386308)
Timeframe: Reduction from Baseline over 6 menstrual cycles
| Intervention | percentage of subjects (Number) |
|---|---|
| 3900 mg/Day | 57 |
| Placebo | 51 |
reduction of menstrual blood loss in mL (NCT00401193)
Timeframe: Baseline MBL over 3 menstrual cycles
| Intervention | mL (Least Squares Mean) |
|---|---|
| 3900 mg/Day | 65 |
| 1950 mg/Day | 44 |
| Placebo | 7 |
A positive unit change of the mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited (NCT00401193)
Timeframe: Baseline scores over 3 menstrual cycles
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 3900 mg/Day | 1.0 |
| Placebo | 0.4 |
A positive unit change of the mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited (NCT00401193)
Timeframe: Baseline scores over 3 menstrual cycles
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 3900 mg/Day | 0.9 |
| Placebo | 0.3 |
Percentage of subjects who experienced a reduction from baseline in the frequency of large stains (NCT00401193)
Timeframe: Baseline over 3 mentrual cycles
| Intervention | percentage of participants (Number) |
|---|---|
| 3900 mg/Day | 64 |
| Placebo | 52 |
Number of subjects who died, for any reason, during the study (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 1 |
The total number of subjects who withdrew from the study due to an adverse event irrespective of the causal relation between the AE and the study drug as determined by the investigator (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 97 |
Examples include deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, central retinal artery and vein obstruction. (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 0 |
An adverse event is any untoward, undesired, unplanned clinical event in the form of signs. symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study with a sponsor study drug, regardless of causal relationship. (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 678 |
The causal relation between an adverse event and the study drug was determined by the investigator on the basis of his or her clinical judgment. A definitely treatment-related adverse event is an event that can be fully explained by administration of the study drug. (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 13 |
A life-threatening AE is any AE that places the subject at immediate risk of death from the event as it occurred. (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 2 |
The causal relation between an adverse event and the study drug was determined by the investigator on the basis of his or her clinical judgment. A possibly treatment-related adverse event is an event that may be explained by administration of the study drug or by the subjects's clinical state or other agents/therapies. (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 306 |
The causal relation between an adverse event and the study drug was determined by the investigator on the basis of his or her clinical judgment. A probably treatment-related adverse event is an event most likely to be explained by administration of the study drug rather than the subjects's clinical state or other agents/therapies. (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 40 |
A serious adverse event (SAE) is any adverse event (AE) occurring at any dose that meets 1 or more of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in a persistent or significant disability or incapacity; results in cancer; results in a congenital anomaly or birth defect. Important medical events not described above may be considered SAEs when based on appropriate medical judgment. (NCT00113568)
Timeframe: Up to 27 menstrual cycles
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid Tablets (XP12B) | 28 |
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
47 reviews available for tranexamic acid and Heavy Menstrual Bleeding
| Article | Year |
|---|---|
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.
Topics: Acetaminophen; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dysmenorrhea; Female; Hum | 2022 |
Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review.
Topics: Female; Hemorrhage; Humans; Menorrhagia; Prospective Studies; Tranexamic Acid; von Willebrand Diseas | 2023 |
Cyclical progestogens for heavy menstrual bleeding.
Topics: Danazol; Female; Humans; Intrauterine Devices, Medicated; Medroxyprogesterone Acetate; Menorrhagia; | 2019 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
Progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Topics: Antifibrinolytic Agents; Contraceptives, Oral; Endometrium; Female; Humans; Hysterectomy; Intrauteri | 2020 |
Which medications work best for menorrhagia?
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Contraceptive A | 2020 |
Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Deamino Arginine Vasopressin; Disease Manageme | 2021 |
Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Contraceptives, Oral; Expert Testimon | 2017 |
Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders.
Topics: Adolescent; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Female; Humans; Menorrhagia; Me | 2018 |
Antifibrinolytics for heavy menstrual bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Ethamsylate; Female; Hemostatics; | 2018 |
Applications of Tranexamic acid in benign gynecology.
Topics: Administration, Oral; Blood Loss, Surgical; Female; Gynecologic Surgical Procedures; Humans; Infusio | 2019 |
Nonsurgical management of heavy menstrual bleeding: a systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Dy | 2013 |
Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.
Topics: Adult; Blood Coagulation Disorders; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Menor | 2014 |
Medical management of heavy menstrual bleeding: a comprehensive review of the literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Contraceptives, Oral, Hormonal; Fe | 2015 |
The medical management of abnormal uterine bleeding in reproductive-aged women.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antifibrinolytic Agents; Blood Coagu | 2016 |
Von Willebrand factor for menorrhagia: a survey and literature review.
Topics: Antifibrinolytic Agents; Contraceptives, Oral; Databases, Factual; Deamino Arginine Vasopressin; Fem | 2016 |
Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Blood Loss, Surgic | 2017 |
Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.
Topics: Adult; Blood Coagulation Disorders; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Menor | 2016 |
Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Blood Coagulation Disorders; Contraceptives, Oral, Combi | 2010 |
OTC tranexamic acid for heavy menstrual bleeding?
Topics: Antifibrinolytic Agents; Drug Costs; Female; Humans; Menorrhagia; Nonprescription Drugs; Practice Gu | 2011 |
Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Female; Humans; Menorrhagia; Randomized Controlle | 2011 |
[Drug therapy of menstruation related complaints].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraceptives, Oral, Hormonal; Dysmenorrhea; Female; Human | 2011 |
Tranexamic acid therapy for heavy menstrual bleeding.
Topics: Antifibrinolytic Agents; Female; Humans; Menorrhagia; Menstruation; Randomized Controlled Trials as | 2011 |
Nonhormonal treatments for heavy menstrual bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Clinical Trials as Topic; Female; | 2011 |
Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy.
Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Meno | 2011 |
Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review.
Topics: Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid; Treatment Outcome | 2012 |
Abnormal uterine bleeding and dysfunctional uterine bleeding in pediatric and adolescent gynecology.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Child; Contraceptives, | 2013 |
Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach.
Topics: Administration, Intravaginal; Algorithms; Antifibrinolytic Agents; Contraceptive Agents, Female; Con | 2013 |
[Hypermenorrhoea].
Topics: Contraceptives, Oral; Endometrial Ablation Techniques; Female; Humans; Menorrhagia; Tranexamic Acid | 2013 |
Therapies for the treatment of abnormal uterine bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraceptives, Oral; Danazol; Endometrium; Estrogens, Conj | 2001 |
Menorrhagia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Danazol; Female; Humans; Hysterectomy; Hysteroscopy; Menorr | 2002 |
Menorrhagia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Danazol; Female; Humans; Hysterectomy; Hysteroscopy; Menorr | 2002 |
Tranexamic acid: a review of its use in the management of menorrhagia.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Female; Humans; Menorrhagia; Tranexamic Acid | 2003 |
Tranexamic acid: a review of its use in the management of menorrhagia.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Female; Humans; Menorrhagia; Tranexamic Acid | 2003 |
Tranexamic acid: a review of its use in the management of menorrhagia.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Female; Humans; Menorrhagia; Tranexamic Acid | 2003 |
Tranexamic acid: a review of its use in the management of menorrhagia.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Female; Humans; Menorrhagia; Tranexamic Acid | 2003 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Menorrhagia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Danazol; Female; Humans; Hysterectomy; Menorrhagia; Tranexa | 2003 |
Menorrhagia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Female; Gonadotropin-Releasing Hor | 2004 |
Menorrhagia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Danazol; Female; Gonadotropin-Releasing Hormone; Humans; Hy | 2005 |
Women and von Willebrand disease: controversies in diagnosis and management.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Contraceptives, Oral, Synthetic; Deamino Arginine Vasopr | 2006 |
A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraceptives, Oral, Combined; Danazol; Deamino Arginine V | 2008 |
Menorrhagia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraceptives, Oral, Combined; Danazol; Female; Humans; In | 1993 |
Fortnightly review. Medical management of menorrhagia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Fe | 1999 |
Medical management of dysfunctional uterine bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Da | 1999 |
Antifibrinolytics for heavy menstrual bleeding.
Topics: Antifibrinolytic Agents; Female; Humans; Menorrhagia; Norethindrone; Tranexamic Acid | 2000 |
Antifibrinolytics for heavy menstrual bleeding.
Topics: Antifibrinolytic Agents; Female; Humans; Menorrhagia; Norethindrone; Randomized Controlled Trials as | 2000 |
Local fibrinolysis as a mechanism for haemorrhage.
Topics: Aminocaproates; Endometrium; Epistaxis; Female; Fibrinolysis; Gastric Juice; Gastrointestinal Hemorr | 1975 |
Indications for antifibrinolytic therapy.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav | 1975 |
[Treatment of menorrhagia].
Topics: Female; Humans; Hysterectomy; Intrauterine Devices, Medicated; Menorrhagia; Prostaglandin Antagonist | 1991 |
32 trials available for tranexamic acid and Heavy Menstrual Bleeding
| Article | Year |
|---|---|
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Topics: Adolescent; Adult; Cross-Over Studies; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Tranexa | 2023 |
Efficacy of
Topics: Adult; Female; Fruit; Humans; Menorrhagia; Myrtus; Patient Acceptance of Health Care; Plant Preparat | 2020 |
Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Flavo | 2018 |
"Evaluation of the effect of roasted lentil flour (lentil savigh) as a functional food in menstrual bleeding reduction".
Topics: Adult; Female; Flour; Functional Food; Hemorrhage; Humans; Iran; Lens Plant; Menorrhagia; Menstruati | 2019 |
Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid.
Topics: Adult; Antifibrinolytic Agents; Contraceptive Agents, Female; Endometrium; Female; Humans; Medroxypr | 2013 |
Oral Tranexamic Acid versus Combined Oral Contraceptives for Adolescent Heavy Menstrual Bleeding: A Pilot Study.
Topics: Adolescent; Child; Contraceptives, Oral, Combined; Cross-Over Studies; Dose-Response Relationship, D | 2015 |
A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial.
Topics: Antifibrinolytic Agents; Contraceptive Agents, Female; Cost-Benefit Analysis; Female; Humans; Intrau | 2015 |
Comparison of Therapeutic Efficacies of Norethisterone, Tranexamic Acid and Levonorgestrel-Releasing Intrauterine System for the Treatment of Heavy Menstrual Bleeding: A Randomized Controlled Study.
Topics: Adult; Anemia; Female; Hemostatics; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Menorrh | 2016 |
[A multicenter prospective randomized open comparative study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China].
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Menstruation; Mid | 2008 |
Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antifibrinolytic Agents; Cross-Over Studies | 2009 |
Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Aza Compounds; Cross-Over Studies; Dose-Respon | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Human | 2010 |
Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Endpoint Determination; Female; Hum | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Cost of Illness; Female; Humans; Menorrh | 2010 |
Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Delayed-Action Preparations; Diet, | 2012 |
A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Double-Blind | 2011 |
Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Middle Aged; Quality of Lif | 2011 |
Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug-Related Side Effects and Adver | 2011 |
Levonorgestrel intrauterine system versus medical therapy for menorrhagia.
Topics: Adult; Antifibrinolytic Agents; Contraceptive Agents, Female; Estrogens; Female; Follow-Up Studies; | 2013 |
Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Contraceptives, Oral, Synthetic; Female; Humans; Medroxy | 2006 |
Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women.
Topics: Adult; China; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Intrauterine De | 2007 |
Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices.
Topics: Adult; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Diclofenac; Double-Blind Method; Femal | 1983 |
[Treatment of hypermenorrhea with tranexamic acid].
Topics: Adolescent; Adult; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Method; Femal | 1983 |
Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Menorrhagia; Middle Aged; Norethindron | 1995 |
[Treatment of menorrhagia with tranexamic acid. A clinical trial of an underestimated problem in general practice].
Topics: Adult; Double-Blind Method; Family Practice; Female; Humans; Menorrhagia; Middle Aged; Tranexamic Ac | 1993 |
Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid.
Topics: Adult; Antifibrinolytic Agents; Cyclooxygenase Inhibitors; Ethamsylate; Female; Hemostatics; Humans; | 1996 |
A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss.
Topics: Adult; Danazol; Endoscopy; Estrogen Antagonists; Female; Humans; Hysteroscopy; Menorrhagia; Menstrua | 1997 |
Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Clinical Competence; Decision Maki | 1999 |
The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Menorrhagia; Middle Aged; P | 2001 |
Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time.
Topics: Adult; Bleeding Time; Cross-Over Studies; Deamino Arginine Vasopressin; Double-Blind Method; Female; | 2002 |
Vaginal absorption of low-dose tranexamic acid from impregnated tampons.
Topics: Absorption; Adult; Female; Humans; Menorrhagia; Tampons, Surgical; Tranexamic Acid; Vagina | 1992 |
An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia.
Topics: Adult; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Flurbiprofen; Humans; Menorrha | 1988 |
57 other studies available for tranexamic acid and Heavy Menstrual Bleeding
| Article | Year |
|---|---|
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
Topics: Female; Humans; Menorrhagia; Postpartum Hemorrhage; Pregnancy; Systematic Reviews as Topic; Tranexam | 2022 |
Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio.
Topics: Female; Humans; Hyperpigmentation; Melanosis; Menorrhagia; Odds Ratio; Quality of Life; Retrospectiv | 2022 |
Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION SUMMARY, Number 785.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Disorders; Contraceptive Agents; Contraceptiv | 2019 |
Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785.
Topics: Adolescent; Antifibrinolytic Agents; Blood Coagulation Disorders; Contraceptive Agents; Contraceptiv | 2019 |
Hemophilia A in Females: Considerations for Clinical Management.
Topics: Adolescent; Aged; Chromosome Inversion; Deamino Arginine Vasopressin; Disease Management; Drug Subst | 2020 |
Decline in Danish use of oral tranexamic acid with increasing use of the levonorgestrel-releasing intrauterine system: a nationwide drug utilization study.
Topics: Adolescent; Adult; Denmark; Drug Utilization; Female; Humans; Hysterectomy; Intrauterine Devices, Me | 2020 |
Bilateral pulmonary embolism while receiving tranexamic acid: a case report.
Topics: Chest Pain; Emergency Service, Hospital; Female; Humans; Menorrhagia; Middle Aged; Pulmonary Embolis | 2020 |
Concomitant use of combined hormonal contraceptives and antifibrinolytic agents for the management of heavy menstrual bleeding: A practice pattern survey.
Topics: Antifibrinolytic Agents; Contraceptives, Oral, Hormonal; Female; Humans; Menorrhagia; Surveys and Qu | 2021 |
Central retinal artery occlusion in a 30-year-old woman taking tranexamic acid.
Topics: Adult; Antifibrinolytic Agents; Female; Fluorescein Angiography; Humans; Menorrhagia; Retinal Artery | 2017 |
How I treat heavy menstrual bleeding associated with anticoagulants.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Me | 2017 |
Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception?
Topics: Antifibrinolytic Agents; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Humans; | 2018 |
An Open-Label, Single-Arm, Efficacy Study of Tranexamic Acid in Adolescents with Heavy Menstrual Bleeding.
Topics: Administration, Oral; Adolescent; Antifibrinolytic Agents; Child; Female; Humans; Menorrhagia; Menst | 2019 |
Heavy menstrual bleeding.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Contraceptives, Oral, Combi | 2013 |
Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Female; Humans; Leiomyoma; Menorrhagia; Middle | 2013 |
[Cardiac arrest caused by massive pulmonary embolism during treatment with tranexamic acid].
Topics: Acute Disease; Adult; Antifibrinolytic Agents; Cardiopulmonary Resuscitation; Fatal Outcome; Female; | 2013 |
Tranexamic acid and thrombosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hematuria; Hemorrhage; Humans; Menorrhagia; R | 2013 |
Tranexamic acid overdosage-induced generalized seizure in renal failure.
Topics: Anticonvulsants; Antifibrinolytic Agents; Drug Overdose; Female; Humans; Kidney; Menorrhagia; Middle | 2014 |
Intratumoral Vasculopathy in Leiomyoma Treated With Tranexamic Acid.
Topics: Female; Humans; Hysterectomy; Leiomyoma; Menorrhagia; Middle Aged; Necrosis; Telangiectasia, Heredit | 2017 |
The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Antifibrinolytic Agents; Databases, Factual; Epidemiolog | 2009 |
[Update on current care guidelines: evaluation and treatment of menorrhagia].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Contraceptive Agents, Female; Fema | 2010 |
Tranexamic acid (Lysteda) for treatment of menorrhagia.
Topics: Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid | 2010 |
von Willebrand disease in the pediatric and adolescent population.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Contusions; Deamino Arginine Vasopres | 2010 |
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Topics: Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid | 2011 |
Antifibrinolytics in women with menorrhagia.
Topics: Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid | 2011 |
PURLs: consider this option for heavy menstrual bleeding.
Topics: Adult; Antifibrinolytic Agents; Female; Follow-Up Studies; Humans; Menorrhagia; Menstruation; Tranex | 2011 |
Tranexamic acid--a recipe for saving lives in traumatic bleeding.
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Menorrhagia; Randomized Controlled Trials | 2011 |
Tranexamic acid increases hemoglobin and ferritin levels in women with heavy menstrual bleeding.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Antifibrinolytic Agents; Female; Ferric Compounds; Ferri | 2012 |
Trends in the surgical options for the treatment of menorrhagia in Scotland: examination of health episode statistics, 2000-2008.
Topics: Adult; Catheter Ablation; Endometrium; Female; Hormone Replacement Therapy; Humans; Hysterectomy; La | 2012 |
Daily menstrual blood loss and quality of life in women with heavy menstrual bleeding.
Topics: Activities of Daily Living; Adult; Antifibrinolytic Agents; Female; Ferritins; Gynecological Examina | 2012 |
The great deception: tranexamic acid and extensive pulmonary emboli.
Topics: Anticoagulants; False Negative Reactions; Female; Fibrin Fibrinogen Degradation Products; Heparin; H | 2013 |
High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2002 |
Combined treatment with tranexamic acid and oral contraceptive pill causes coronary ulcerated plaque and acute myocardial infarction.
Topics: Adult; Chest Pain; Contraceptives, Oral; Coronary Angiography; Coronary Vessels; Drug Therapy, Combi | 2004 |
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.
Topics: Adult; Anemia, Iron-Deficiency; Antifibrinolytic Agents; Blood Coagulation Tests; Female; Hemorrhagi | 2004 |
Menorrhagia due to abnormalities of the platelet function: evaluation of two young patients.
Topics: Adolescent; Antifibrinolytic Agents; Bernard-Soulier Syndrome; Comorbidity; Deamino Arginine Vasopre | 2007 |
Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Female; Humans; Infarction; Leiomyoma; Meno | 2007 |
Treatment of idiopathic menorrhagia with tranexamic acid.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Middl | 2005 |
Development and evaluation of an inhibitor-releasing matrix for intrauterine devices.
Topics: Animals; Antifibrinolytic Agents; Aprotinin; Female; In Vitro Techniques; Intrauterine Devices, Medi | 1982 |
The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding.
Topics: Adolescent; Endometrium; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysis; Humans; Menorrhagi | 1994 |
[Treatment (and diagnosis) of menorrhagia].
Topics: Female; Humans; Menorrhagia; Tranexamic Acid | 1993 |
Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Leiomyoma; Menorrhagia; Tranexamic Acid; Uterine Neo | 1998 |
Is medical management of menorrhagia obsolete?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Estrogen Replacement Therapy; Female; Humans; Hyster | 1998 |
Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Drug Administration Schedule; Fema | 1998 |
Treatment of menorrhagia in von Willebrand's disease.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid; von Willebrand Disease | 1999 |
10 minute consultation: menorrhagia.
Topics: Anemia, Iron-Deficiency; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Clinical | 2000 |
First-line management of menorrhagia: findings from a survey of general practitioners in Forth Valley.
Topics: Data Collection; Family Practice; Female; Health Care Surveys; Humans; Mefenamic Acid; Menorrhagia; | 2000 |
Management of menorrhagia: an audit of practices in the Anglia menorrhagia education study.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Education, Medical, Continuing; England; Female; Humans; | 2001 |
The use of tranexamic acid (AMCA) in IUDs as an anti-bleeding agent.
Topics: Adult; Cyclohexanecarboxylic Acids; Female; Humans; Intrauterine Devices; Intrauterine Devices, Medi | 1976 |
Hemorrhage induced by intrauterine devices: control by local proteinase inhibition.
Topics: Administration, Topical; Cyclohexanecarboxylic Acids; Female; Humans; Intrauterine Devices, Copper; | 1977 |
Fibrinogen-fibrin degradation products in menstrual blood from women with normal and excessive menstrual losses.
Topics: Adult; Female; Fibrin; Fibrinogen; Humans; Menorrhagia; Menstruation; Middle Aged; Time Factors; Tra | 1975 |
[Possibilities of the use of an inhibitor of hemolysis (AMCHA), by rectal and vaginal administration, for gynecological hemorrhages].
Topics: Adolescent; Adult; Aged; Blood Coagulation Disorders; Child; Cyclohexanecarboxylic Acids; Female; He | 1975 |
[Role of fibrinolysis in excessive menstrual bleeding].
Topics: Antifibrinolytic Agents; Female; Fibrinolysis; Humans; Menorrhagia; Tranexamic Acid | 1976 |
A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia.
Topics: Adult; Female; Flurbiprofen; Hemoglobins; Humans; Hysterectomy; Intrauterine Devices; Levonorgestrel | 1991 |
Management of IUD-associated menorrhagia in female rhesus monkeys (Macaca mulatta).
Topics: Aminocaproic Acid; Animals; Anti-Inflammatory Agents; Antifibrinolytic Agents; Endometrium; Female; | 1991 |
Modern treatment of menorrhagia.
Topics: Female; Humans; Long-Term Care; Menorrhagia; Tranexamic Acid | 1990 |
Central venous stasis retinopathy following the use of tranexamic acid.
Topics: Adult; Female; Fluorescein Angiography; Fundus Oculi; Humans; Leukocyte Count; Menorrhagia; Retinal | 1990 |
The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid.
Topics: Administration, Oral; Adult; Cyclohexanecarboxylic Acids; Female; Fibrinolysin; Humans; Menorrhagia; | 1987 |
[Prevention and treatment of IUD-induced menorrhagia with antifibrinolytic and antiprostaglandin drugs].
Topics: Adult; Copper; Cyclohexanecarboxylic Acids; Drugs, Chinese Herbal; Female; Flufenamic Acid; Humans; | 1987 |